4.5 Review

Pediatric low-grade gliomas and the need for new options for therapy Why and how?

Journal

CANCER BIOLOGY & THERAPY
Volume 8, Issue 1, Pages 4-10

Publisher

TAYLOR & FRANCIS INC
DOI: 10.4161/cbt.8.1.7237

Keywords

gliomas; pilocytic astrocytoma; pediatric; therapy; neurofibromatosis; tuberous sclerosis; low-grade

Categories

Funding

  1. Cancer Center Support (CORE) [P30 CA21765]
  2. National Institutes of Health
  3. American Lebanese Syrian Associated Charities (ALSAC)
  4. Pediatric Brain Tumor Foundation
  5. Noyes Brain Tumor Foundation
  6. Ryan McGhee Foundation
  7. Musicians Against Childhood Cancer (MACC).
  8. NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Pediatric low-grade gliomas are the most common tumors of the central nervous system in children, accounting for almost 50% of all childhood brain tumors. They are a heterogeneous group of tumors with different histologic subtypes. Most treatment studies address low-grade gliomas as a single entity, depriving us of histology-specific treatment outcomes. This is mostly due to a lack of understanding of tumor biology at the molecular level. Pediatric low-grade gliomas are not benign and most incompletely resected tumors will progress and negatively affect quality of life. The advancements made in understanding sporadic pilocytic astrocytoma and neurofibromatosis I-associated pilocytic astrocytoma in particular have paved the way for potential targeted therapy and biological stratification. Such progress in pilocytic astrocytoma needs to be consolidated and expanded to other histologic varieties of pediatric low-grade gliomas.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available